Latest Candel Therapeutics News & Updates

See the latest news and media coverage for Candel Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Candel Therapeutics

Clinical-stage biotech developing viral immunotherapy platforms for solid tumors

candeltx.com

Headquarters: Needham, United States
Founded year: 1999
Company type: Public company
Number of employees: 90–200

Last updated Today

Latest news about Candel Therapeutics

In short: Candel Therapeutics reported pivotal phase 3 data for its prostate cancer therapy and finalized plans for a BLA submission in late 2026.

Company announcements

June 2 Candel Therapeutics

Candel Therapeutics announces Lancet Oncology phase 3 publication

The publication reports a pivotal phase 3 trial showing 30% improvement in disease-free survival with aglatimagene plus radiotherapy and supports a planned BLA submission in Q4 2026.

May 15 Candel Therapeutics

Candel Therapeutics reports extended clinical benefit in prostate cancer trial

Phase 3 trial of CAN-2409 shows 39% improvement in disease-free survival after prolonged follow-up, reinforcing potential to reduce tumor recurrence.

May 14 Candel Therapeutics

Candel Therapeutics announced Q1 2026 results and clinical updates

The company is developing CAN-2409 for prostate and lung cancer, and CAN-3110 for recurrent high-grade glioma.

May 6 Candel Therapeutics

Candel Therapeutics presents phase 2 data for CAN-2409

Data shows 50% of NSCLC patients surviving beyond 24 months, supporting phase 3 trial initiation.

Media coverage

June 12 MSN

Aglatimagene besadenovec + valacyclovir ups DFS in localized prostate cancer

For patients with localized prostate cancer, aglatimagene besadenovec, an adenoviral-based immunotherapy, plus valacyclovir is associated with longer disease-free survival (DFS) than placebo plus valacyclovir when...

June 2 The Globe and Mail

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene ...

Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with curative intent...

May 23 American Banking News

Candel Therapeutics (NASDAQ:CADL) Lowered to Sell Rating by Wall Street Zen - American Market News

Candel Therapeutics (NASDAQ:CADL – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in...

May 20 Yahoo Finance

Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data

Chief Executive Officer Dr. Paul Peter Tak said the company remains focused on advancing its viral immunotherapy programs following newly presented prostate cancer data and...

Never miss news about Candel Therapeutics

Track Candel Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Candel Therapeutics competitors & trending companies

Browse news for competitors to Candel Therapeutics and other trending companies.